Clinical Trial Update: Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium [Phase 2]

View source ↗

Summary

A Phase 2 trial of Vorinostat for locally recurrent or metastatic urothelial cancers was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transitional Cell Carcinoma of the Bladder
• Transitional Cell Carcinoma of the Renal Pelvis
• Transitional Cell Carcinoma of the Ureter

Drugs mentioned

• Zolinza (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Status: TERMINATED | Results posted: 2015-02-13